Orphan drug development is one of the more fraught undertakings in biomedical research. Targeting rare diseases often requires cutting-edge science, but science is not […]
“What does good advocacy look like? Why do we advocate? And what are some tips and tricks for effective advocacy?” asked Karin Hoelzer, Senior
Patient Advocacy Coffee Chat: Basic steps to being a good advocate Read More »
Changes brought on by the Inflation Reduction Act (IRA) often increase patient costs and reduce access, while also harming the innovation that brings new
PACE panel notes challenges IRA poses for patients Read More »
The law guiding U.S. drug approval was created to meet the demands of patient advocates, and the patient community still shapes the process. Stakeholders
PACE panel lays out patient input possibilities in PDUFA VIII Read More »
The most dangerous antimicrobial-resistant (AMR) pathogens in America are causing an estimated 9.7 million infections and 50,800 deaths in the U.S. each year, says
CDC report details impact of AMR pathogens Read More »
BIO praised a Food and Drug Administration (FDA) initiative targeting more tailored, patient-centered, and predictable development of rare disease drugs, while recommending ways to
BIO supports FDA’s new Fit-for-Purpose Rare Disease Framework Initiative Read More »
The United States leads the world in biotech innovation, and a major driver is its strong intellectual property (IP) system. In fact, IP rights
IP: American as apple pie and essential for biotech Read More »
The latest portrait of America’s biotech industry describes a growing economic force responsible for $3.19 trillion in total U.S. economic output and employment of
2026 report on biotech’s economic impact portrays a vast ecosystem Read More »
Breakthrough therapies can change the lives of patients who previously had few or no treatments for their conditions, but only if the patients can
PACE panels tackle challenges to access and barriers to coverage Read More »
Patient advocates are no strangers to the sometimes painful challenges of promoting access to medicines and treatments. The key, they say, is staying two
PACE: Pushing past the pain to achieve access for the 21st Century Read More »
